Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
OverviewMechanism of ActionHow To UseUsesBenfitsIndicationsMethod of AdministrationDosage StrengthsDosage FormsDietary RestrictionsContraindicationsWarnings and Precautions for usingSide EffectsClinical Pharmacology Clinical StudiesAuthored by Reviewed by References
Oxaceprol

Oxaceprol

Indications, Uses, Dosage, Drugs Interactions, Side effects
Oxaceprol
Medicine Type :
Allopathy
Prescription Type:
Prescription Required
Approval :
DCGI (Drugs Controller General of India)
Schedule
Schedule H
Pharmacological Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs),
Therapy Class:
Amino-acid derivatives,

Oxaceprol is a Amino-acid derivatives. belonging to Non-Steroidal anti-inflammatory Drug

Oxaceprol is used in the treatment of osteoarthritis and inflammatory connective tissue diseases.

Oxaceprol is absorbed 3.5 hr after oral admin and get permeates into the synovial fluid. Bio-availability after oral admin: approx 30% and excreted via urine (exclusively, unchanged and complete). And elimination half-life: 2.2 hr.

Oxaceprol is available in tablets.

The common side effects of Oxaceprol was Dizziness, Nausea, Diarrhea, Abdominal pain, Itching, Weakness.

Oxaceprol is available in India, Germany, Canada, France, USA.

Oxaceprol blocks the release of certain chemical mediators responsible for pain, redness, swelling, etc. thereby providing relief in inflammatory conditions of bones and joints.

Oxaceprol is available in the form of tablets.

Oxaceprol is used in the treatment of osteoarthritis and inflammatory connective tissue diseases.

Oxaceprol is an anti-inflammatory medication. It works by preventing accumulation of leukocytes in the joints, thus inhibiting inflammation at an early stage. This helps in pain relief.

Oxaceprol is approved for use in the following clinical indications

  • Osteoarthritis

This medicine is used to relieve symptoms such as pain and swelling associated with osteoarthritis of the knee or hip joints.

  • Inflammatory connective tissue diseases

This medicine is used to relieve symptoms such as pain and swelling associated with inflammatory connective tissue diseases such as rheumatoid arthritis, bursitis, periarthritis, etc.

Oral

Degenerative joint disorders

Adult: 200 mg tid. In severe cases, initial dose can be increased to 400 mg tid. Taken before a meal, unchewed.

Elderly: Dose reduction is recommended.

Oral

Inflammatory connective tissue diseases

Adult: 200 mg tid. In severe cases, initial dose can be increased to 400 mg tid. Taken before a meal, unchewed.

Elderly: Dose reduction is recommended.

Topical/Cutaneous

Superficial burns

Adult: 10% cream: Apply once a day.

Oxaceprol is available in the dosage strength of 600 mg

Oxaceprol is available in the form of tablets.

Take after eating and with a full glass of water to decrease gastric upset.

Oxaceprol is contraindicated in patients with:

Oxaceprol should not be administered to animals with serious hepatic, renal or cardiac pathology, or those with a history of blood dyscrasia.

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

General warnings

Kidney impairment

This medicine should be used with caution in patients suffering from kidney diseases due to the increased risk of severe adverse effects. Close monitoring of kidney function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Alcohol Warning

Oxaceprol may cause liver problems, and using it with substantial quantities of ethanol may increase that risk.

Breast Feeding Warning

Oxaceprol and its active metabolite morphine are present in breast milk and can be detected in the serum of breastfeeding infants.

Concentrations of Oxaceprol and morphine in breast milk are dependent upon the mother's CYP2D6 metabolism. In patients with normal CYP2D6 metabolism, the amount detected in breast milk is expected to be dose-dependent; however, deaths have occurred in breastfeeding infants exposed to high concentrations of morphine because the mothers were ultrarapid metabolizers. Genetic testing for CYP2D6 is recommended for patients requiring Oxaceprol for postpartum pain and who will be breastfeeding

Affects coagulation in patients under anticoagulative therapy with Vitamin K-antagonists. May decrease effects of anti-hypertensives. May affect toxicity of methotrexate and lithium.

The common side effects of Oxaceprol include the following :

Common Side effects: Gastric pain, nausea, diarrhea, dizziness, headache and skin rashes.

  • Pharmacodynamics

It affects connective tissue metabolism and has been used in dermatology, to promote wound healing, and in rheumatic disorders. Experimental models of arthritis showed that oxaceprol reduced leukocyte extravasation, as well as the adhesion of leukocytes to capillaries. In vitro studies have shown that oxaceprol stimulates the uptake of 3H-glucosamine and 3H-proline in chondrocytes and the incorporation of 3H-proline in the macromolecular structure of the matrix of cartilage; which would be responsible for the activity on regenerating tissue.

  • Pharmacokinetics

Absorption: 3.5 hr after oral admin.

Distribution: Permeates into the synovial fluid. Bio-availability after oral admin: approx 30%.

Excretion: Via urine (exclusively, unchanged and complete). Elimination half-life: 2.2 hr.

There are some clinical studies of the drug Oxaceprol mentioned below:
  1. https://pubmed.ncbi.nlm.nih.gov/1091001/
  2. https://clinicaltrials.gov/ct2/show/NCT01422915
  3. https://clinicaltrials.gov/ct2/show/NCT02263547
  4. https://www.medicines.org.uk/emc/product/128/smpc.

  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364710/
  2. https://reference.medscape.com/drug/colestid-Oxaceprol -342452
  3. https://go.drugbank.com/drugs/DB00375
  4. https://www.sciencedirect.com/topics/medicine-and-dentistry/Oxaceprol
  5. https://europepmc.org/article/med/6988203
undefined
Parthika Patel
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
undefined
Dr JUHI SINGLA
Dr JUHI SINGLA has completed her MBBS from Era’s Lucknow Medical college and done MD pharmacology from SGT UNIVERSITY Gurgaon. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Published on: 26 July 2023 2:59 PM GMT
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok